Patrick Bilbo - 18 Feb 2026 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
Chief Operating Officer
Signature
/s/ William R. Kolb, Attorney-in-Fact
Issuer symbol
ORGO
Transactions as of
18 Feb 2026
Net transactions value
-$62,254
Form type
4
Filing time
20 Feb 2026, 17:28:06 UTC
Previous filing
18 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bilbo Patrick Chief Operating Officer C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD, CANTON /s/ William R. Kolb, Attorney-in-Fact 20 Feb 2026 0001759203
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Award $0 +210,937 +24% $0.000000 1,095,585 18 Feb 2026 Direct F1
transaction ORGO Class A Common Stock Award $0 +48,612 +4.4% $0.000000 1,144,197 18 Feb 2026 Direct F2
transaction ORGO Class A Common Stock Tax liability $62,254 -16,212 -1.4% $3.84 1,127,985 18 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Award $0 +120,267 $0.000000 120,267 18 Feb 2026 Class A Common Stock 120,267 $3.84 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026.
F2 Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones.
F3 The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.